Novartis AG

Approval AI-extracted

del-brax

f acioscapulohumeral muscular dystrophy (FSHD)

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on del-brax for f acioscapulohumeral muscular dystrophy (FSHD) is expected Date TBD.

Primary source · SEC 6-K verified 12h ago

“del-brax is the only investigational agent showing disease-modifying potential for FSHD in clinical studies.”